

Supplemental Online Content

Back AL, Freeman-Young TK, Morgan L, et al. Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: a randomized clinical trial. *JAMA Netw Open*. 2024;7(12):e2449026.
doi:10.1001/jamanetworkopen.2024.49026

eTable. Functional Unblinding Questions

eFigure. Study Flow Diagram

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable. Functional Unblinding Questions

"Which treatment do you believe you received: the psilocybin or the niacin?"
(just after capsule was swallowed)

Group	"psilocybin"	"niacin"	"don't know"
Psilocybin	0	0	15 (100%)
Placebo	0	0	15 (100%)

"Which treatment do you believe you received: the active drug or the placebo?"
(asked just before discharge from the psilocybin or placebo session)

Group	"psilocybin"	"niacin"	"don't know"	Correct at unblinding
Psilocybin	0	0	15 (100%)	15 (100%)
Placebo	0	0	15 (100%)	15 (100%)

eFigure. Study Flow Diagram

Figure legend. The days are numbered using Day 0 as the day of the psilocybin or niacin session. Prep = Preparation session. Integ = Integration session. Baseline measures were completed just before Prep 1.

